New incident report
Incident Report Number: 2011-4296
Registrant Reference Number: PROSAR Case # 1-26978487
Registrant Name (Full Legal Name no abbreviations): Scotts Canada Ltd.
Address: 2000 Argentia Road, Plaza 5, Suite 101
City: Mississauga
Prov / State: Ontario
Country: Canada
Postal Code: L5N2R7
Human
Country: CANADA
Prov / State: ONTARIO
PMRA Registration No. 27520 PMRA Submission No. EPA Registration No.
Product Name: Home Defense Max Perimeter Indoor Insect Control
Yes
Unknown
Site: Unknown / Inconnu
Unknown
Data Subject
Sex: Male
Age: >19 <=64 yrs / >19 <=64 ans
System
Unknown / Inconnu
Unknown
Unknown
Non-occupational
Application
Unknown
Unknown
Unknown / Inconnu
>1 wk <=1 mo / > 1 sem < = 1 mois
1-26978487- The reporter indicates he and a friend may have been exposed to an insecticide containing the active ingredient permethrin. The reporter indicates an adult friend (Subform II, #1) of his used the product two weeks prior to his initial contact with the registrant. The reporter indicated this friend had been experiencing hallucinations and speaking in a 'ridiculous manner' following use of the product. The reporter did not describe the application or the onset of the symptoms seen. The reporter indicated he did not observe exposure but did observe the behavior. The reporter indicated he did personally (Subform II, #2) experience transitory muscle weakness while the previously described patient demonstrated the abnormal behavior. The reporter was advised the observed symptoms would not be expected following exposure to this product by any avenue. He was advised to seek medical assistance in determining the cause of the observed symptoms and if treatment is necessary. No further information is available
Moderate
Data Subject
Sex: Male
Age: >19 <=64 yrs / >19 <=64 ans
System
Unknown / Inconnu
Unknown
Unknown
Unknown
Application
Unknown
Unknown
Unknown / Inconnu
Unknown / Inconnu
1-26978487- The reporter indicates he and a friend may have been exposed to an insecticide containing the active ingredient permethrin. The reporter indicates an adult friend (Subform II, #1) of his used the product two weeks prior to his initial contact with the registrant. The reporter indicated this friend had been experiencing hallucinations and speaking in a 'ridiculous manner' following use of the product. The reporter did not describe the application or the onset of the symptoms seen. The reporter indicated he did not observe exposure but did observe the behavior. The reporter indicated he did personally (Subform II, #2) experience transitory muscle weakness while the previously described patient demonstrated the abnormal behavior. The reporter was advised the observed symptoms would not be expected following exposure to this product by any avenue. He was advised to seek medical assistance in determining the cause of the observed symptoms and if treatment is necessary. No further information is available
Minor